Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    June 2018
  1. LIU H, He W, Wang B, Xu K, et al
    MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    BMC Cancer. 2018;18:659.
    PubMed     Text format     Abstract available


  2. LIU Y, Wang H, Zhong J, Wu C, et al
    Decreased expression of SRY-box containing gene 30 is related to malignant phenotypes of human bladder cancer and correlates with poor prognosis.
    BMC Cancer. 2018;18:642.
    PubMed     Text format     Abstract available


    May 2018
  3. KWON WA, Joung JY, Lim J, Oh CM, et al
    Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea.
    BMC Cancer. 2018;18:617.
    PubMed     Text format     Abstract available


  4. XIE H, Zhu Y, Zhang J, Liu Z, et al
    B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
    BMC Cancer. 2018;18:590.
    PubMed     Text format     Abstract available


    February 2018
  5. PULIDO M, Roubaud G, Cazeau AL, Mahammedi H, et al
    Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
    BMC Cancer. 2018;18:194.
    PubMed     Text format     Abstract available


  6. SEVERINO PF, Silva M, Carrascal M, Malagolini N, et al
    Oxidative damage and response to Bacillus Calmette-Guerin in bladder cancer cells expressing sialyltransferase ST3GAL1.
    BMC Cancer. 2018;18:198.
    PubMed     Text format     Abstract available


    December 2017
  7. ZHANG Z, Zhang G, Gao Z, Li S, et al
    Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
    BMC Cancer. 2017;17:861.
    PubMed     Text format     Abstract available


    November 2017
  8. HUEBNER D, Rieger C, Bergmann R, Ullrich M, et al
    An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment.
    BMC Cancer. 2017;17:790.
    PubMed     Text format     Abstract available


  9. TAN WS, Feber A, Dong L, Sarpong R, et al
    DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
    BMC Cancer. 2017;17:767.
    PubMed     Text format     Abstract available


  10. TOLKACH Y, Stahl AF, Niehoff EM, Zhao C, et al
    YRNA expression predicts survival in bladder cancer patients.
    BMC Cancer. 2017;17:749.
    PubMed     Text format     Abstract available


    September 2017
  11. NEUZILLET Y, Chapeaublanc E, Krucker C, De Koning L, et al
    IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
    BMC Cancer. 2017;17:636.
    PubMed     Text format     Abstract available


    June 2017
  12. PENG D, Gong YQ, Hao H, He ZS, et al
    Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival with Bladder Cancer after Radical Cystectomy: a retrospective study.
    BMC Cancer. 2017;17:391.
    PubMed     Text format     Abstract available


    May 2017
  13. TEYSSONNEAU D, Daste A, Dousset V, Hoepffner JL, et al
    Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
    BMC Cancer. 2017;17:323.
    PubMed     Text format     Abstract available


  14. FONTEYNE V, Dirix P, Junius S, Rammant E, et al
    Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial.
    BMC Cancer. 2017;17:308.
    PubMed     Text format     Abstract available


    April 2017
  15. KAO YT, Wu CH, Wu SY, Lan SH, et al
    Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells.
    BMC Cancer. 2017;17:277.
    PubMed     Text format     Abstract available


  16. LAVERY HJ, Zaharieva B, McFaddin A, Heerema N, et al
    A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection.
    BMC Cancer. 2017;17:247.
    PubMed     Text format     Abstract available


    March 2017
  17. MIYAKE M, Morizawa Y, Hori S, Marugami N, et al
    Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder.
    BMC Cancer. 2017;17:237.
    PubMed     Text format     Abstract available


    February 2017
  18. DYSHLOVOY SA, Madanchi R, Hauschild J, Otte K, et al
    The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
    BMC Cancer. 2017;17:93.
    PubMed     Text format     Abstract available


    January 2017
  19. BAI Y, Wang X, Yang Y, Tang Y, et al
    Parity and bladder cancer risk: a dose-response meta-analysis.
    BMC Cancer. 2017;17:31.
    PubMed     Text format     Abstract available


    November 2016
  20. KONG C, Zhan B, Piao C, Zhang Z, et al
    Overexpression of UNC5B in bladder cancer cells inhibits proliferation and reduces the volume of transplantation tumors in nude mice.
    BMC Cancer. 2016;16:892.
    PubMed     Text format     Abstract available


  21. BENHAMOU S, Bonastre J, Groussard K, Radvanyi F, et al
    A prospective multicenter study on bladder cancer: the COBLAnCE cohort.
    BMC Cancer. 2016;16:837.
    PubMed     Text format     Abstract available


    January 2016
  22. KAWAHARA T, Furuya K, Nakamura M, Sakamaki K, et al
    Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy.
    BMC Cancer. 2016;16:185.
    PubMed     Text format     Abstract available


  23. LOPEZ DE MATURANA E, Picornell A, Masson-Lecomte A, Kogevinas M, et al
    Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models.
    BMC Cancer. 2016;16:351.
    PubMed     Text format     Abstract available


  24. GARCIA PV, Seiva FR, Carniato AP, de Mello Junior W, et al
    Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
    BMC Cancer. 2016;16:422.
    PubMed     Text format     Abstract available


  25. LI X, Wang H, Wang J, Chen Y, et al
    Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.
    BMC Cancer. 2016;16:578.
    PubMed     Text format     Abstract available


  26. OLDENBURG D, Ru Y, Weinhaus B, Cash S, et al
    CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL).
    BMC Cancer. 2016;16:713.
    PubMed     Text format     Abstract available


  27. ROPERCH JP, Grandchamp B, Desgrandchamps F, Mongiat-Artus P, et al
    Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    BMC Cancer. 2016;16:704.
    PubMed     Text format     Abstract available


  28. ANANTHARAMAN A, Friedlander T, Lu D, Krupa R, et al
    Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    BMC Cancer. 2016;16:744.
    PubMed     Text format     Abstract available


    January 2015
  29. ZHOU B, Zhang P, Tang T, Liao H, et al
    Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer.
    BMC Cancer. 2015;15:433.
    PubMed     Text format     Abstract available


  30. HAYNE D, Stockler M, McCombie SP, Chalasani V, et al
    BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
    BMC Cancer. 2015;15:432.
    PubMed     Text format     Abstract available


  31. KU JH, Kang M, Kim HS, Jeong CW, et al
    Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis.
    BMC Cancer. 2015;15:447.
    PubMed     Text format     Abstract available


  32. LEE JY, Cho KS, Kang DH, Jung HD, et al
    A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging.
    BMC Cancer. 2015;15:566.
    PubMed     Text format     Abstract available


  33. ACAR O, Ozkurt E, Demir G, Sarac H, et al
    Determining the origin of synchronous multifocal bladder cancer by exome sequencing.
    BMC Cancer. 2015;15:871.
    PubMed     Text format     Abstract available


  34. SMOLENSKY D, Rathore K, Cekanova M
    Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
    BMC Cancer. 2015;15:927.
    PubMed     Text format     Abstract available


  35. KIM M, Jeong CW, Kwak C, Kim HH, et al
    Are urothelial carcinomas of the upper urinary tract a distinct entity from urothelial carcinomas of the urinary bladder? Behavior of urothelial carcinoma after radical surgery with respect to anatomical location: a case control study.
    BMC Cancer. 2015;15:149.
    PubMed     Text format     Abstract available


  36. YEH HH, Tseng YF, Hsu YC, Lan SH, et al
    Ras induces experimental lung metastasis through up-regulation of RbAp46 to suppress RECK promoter activity.
    BMC Cancer. 2015;15:172.
    PubMed     Text format     Abstract available


  37. DORES GM, Qubaiah O, Mody A, Ghabach B, et al
    A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992-2010.
    BMC Cancer. 2015;15:185.
    PubMed     Text format     Abstract available


  38. LIU W, Qi L, Lv H, Zu X, et al
    MiRNA-141 and miRNA-200b are closely related to invasive ability and considered as decision-making biomarkers for the extent of PLND during cystectomy.
    BMC Cancer. 2015;15:92.
    PubMed     Text format     Abstract available


  39. RETZ M, de Geeter P, Goebell PJ, Matz U, et al
    Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.
    BMC Cancer. 2015;15:455.
    PubMed     Text format     Abstract available


    January 2014
  40. CASTELLANO D, Puente J, de Velasco G, Chirivella I, et al
    Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
    BMC Cancer. 2014;14:779.
    PubMed     Text format     Abstract available


  41. GREIFE A, Jankowiak S, Steinbring J, Nikpour P, et al
    Canonical Notch signalling is inactive in urothelial carcinoma.
    BMC Cancer. 2014;14:628.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: